3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
fludarabine
23
Cyclophosphamide
23
fludarabine phosphate
18
Tacrolimus
16
ruxolitinib
15
Melphalan
15
Azacitidine
14
venetoclax
13
Whole-Body Irradiation
12
Mycophenolic Acid
12
Cytarabine
11
Busulfan
11
Thiotepa
9
Specimen Handling
9
Stem Cell Transplantation
8
Granulocyte Colony-Stimulating Factor
8
Decitabine
8
Biopsy
8
Peripheral Blood Stem Cell Transplantation
7
Imatinib Mesylate
7
decitabine and cedazuridine drug combination
6
Sirolimus
6
Methotrexate
6
thymoglobulin
5
nilotinib
5
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
bexmarilimab
×
Myeloid
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled